Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
About this study
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.
- Condition
- Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin
- Tested
- Chemotherapy
- Sponsor
- Samsung Medical Center
Who can join
- Age
- 20 to 90 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 20 years
- Maximum age: 90 years
- Study condition: Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin
- Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
- 20 years
- Patients requiring systemic chemotherapy with curative intent
- Written informed consent
Exclusion 3
- Myeloid malignancy
- Multiple myeloma
- Patients do not require systemic chemotherapy with curative intent
Where
1 site, 1 recruiting
Samsung Medical Center
Seoul, South Korea
Contact
-
Seok Jin Kim, MD, PhD
+82234101766 kstwoh@skku.edu
Potential match only. Final eligibility is determined by the study team.